R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US

Global Researchers Call for the Revival of the Human Genome Project to Advance Precision Medicine

BGI GenomicsLON: ONT

Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology

CRO / CMO / CDMOSHE: 300347

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

Eli LillyGene therapy

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Show More